Prasugrel and Wall Street: Lilly Tries to Stop the Bleeding
This article was originally published in RPM Report
Executive Summary
Lilly is in a race against the clock: it is counting on prasugrel to carve out a blockbuster position in the anti-clotting market before 2011. That is when Plavix generics will complicate the anti-clotting marketand Zyprexa generics will complicate Lilly's outlook. But will FDA go along with Lilly's schedule?
You may also be interested in...
Lilly Is Prepared For Potential Prasugrel Advisory Committee
FDA has not yet notified the company of an upcoming advisory panel meeting, executives say.
Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review
It looks like FDA's decision on Lilly's anti-clotting drug prasugrel won't come before March 2009 at the earliest
"Priority" Review Slow Down: The Prasugrel Delay
FDA is looking at a February advisory committee for the Lilly/Daiichi anti-clotting drug. That would put the review of the "priority" application at 14 months and counting. What does prasugrel mean for the priority review process?